Could a switch to analogue insulin reduce dangerous low blood sugar in kids with diabetes?
NCT ID NCT05614089
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 4 trial enrolled 400 youth aged 7-25 with type 1 diabetes in low-resource settings. It compared insulin glargine (a long-acting analogue) to standard human insulin (NPH or premixed) to see if glargine reduces serious hypoglycemia or improves time in blood sugar range over 6 months. Participants used continuous glucose monitors to track outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
insulin glargine (a long-acting insulin analogue)
What this could lead to
If it works, this could show that insulin glargine is safer and more effective than cheaper human insulin for managing type 1 diabetes in low-resource settings.
What could go wrong
This is a completed Phase 4 trial, but results may not apply broadly due to the specific low-resource setting and strict eligibility criteria. The benefits of glargine over human insulin may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BIRDEM Hospital
Dhaka, Bangladesh
-
Bugando Medical Center
Mwanza, Tanzania
-
Sekou-Toure Hospital
Mwanza, Tanzania